Over the past decade, the distribution of Investigational Medicinal Products (IMPs) has become an increasingly complex part of the supply chain for companies involved in new drug development. Clinical studies are becoming ever more globalized as pharmaceutical and biotech companies look to reach new streams of treatment-naïve patients and lucrative potential markets for their products.
While the management of clinical trial logistics is a critical component in the successful development of any new drug or biological product, entry into new markets requires careful consideration of the customs, regulatory, and logistical challenges each country presents.